Background: Deficiency of adenosine deaminase 2 (DADA2) is a rare autoinflammatory disease usually presenting before the age of 10 years. Non-specific clinical features or late-onset presentation may delay its diagnosis until adulthood.

Objective: To determine whether DADA2 diagnosed in adulthood is associated with specific characteristics compared to DADA2 diagnosed in childhood.

Methods: We pooled a cohort of 12 adult DADA2 patients followed in France with cases identified through a systematic literature review. For each patient, we determined the type of clinical presentation and assessed six key organ involvements.

Results: A total of 306 cases were included. Among the 283 patients with available data regarding age at diagnosis, 140 were diagnosed during adulthood and 143 during childhood. The vascular presentation of DADA2 was more frequent in the adult diagnosis group (77.9% vs. 62.9%, p < 0.01), whereas the hematological presentation (bone marrow failure) prevailed in the pediatric diagnosis group (10.0% vs. 20.3% p = 0.02). In patients with vasculopathy, severe skin manifestations developed in 35% and 10% of the adult and pediatric diagnosis groups, respectively. Conversely, fewer strokes occurred in the adult group presenting with systemic vasculopathy (54% vs. 81%). Symptomatic humoral immune deficiency (HID) was rarely a clinical presentation in itself (5% and 2.8%) but accompanied other phenotypes of DADA2, especially the hematological phenotype in the adult group (33% vs. 4%).

Conclusion: DADA2 diagnosed in adulthood presents more often with a vascular phenotype and less often with bone marrow failure than DADA2 diagnosed in childhood. Adults diagnosed with DADA2 vasculopathy display more severe skin involvement but fewer strokes.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semarthrit.2021.09.001DOI Listing

Publication Analysis

Top Keywords

dada2 diagnosed
12
diagnosed adulthood
12
systematic literature
8
literature review
8
dada2
6
adulthood versus
4
versus childhood
4
childhood comparative
4
comparative study
4
study 306
4

Similar Publications

Understanding Parkinson's: The microbiome and machine learning approach.

Maturitas

February 2025

Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Universiteitsweg 99, Utrecht 3508 TB, the Netherlands.

Objective: Given that Parkinson's disease is a progressive disorder, with symptoms that worsen over time, our goal is to enhance the diagnosis of Parkinson's disease by utilizing machine learning techniques and microbiome analysis. The primary objective is to identify specific microbiome signatures that can reproducibly differentiate patients with Parkinson's disease from healthy controls.

Methods: We used four Parkinson-related datasets from the NCBI repository, focusing on stool samples.

View Article and Find Full Text PDF

Dominant negative mutations cause ADA2 deficiency in heterozygous carriers.

medRxiv

December 2024

Laboratory Inborn errors of Immunity, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.

Human ADA2 deficiency (DADA2) is an inborn error of immunity with a broad clinical phenotype which encompasses vasculopathy including livedo racemosa and lacunar strokes, as well as hemato-immunological features. Diagnosis is based on the combination of decreased serum ADA2 activity and the identification of biallelic deleterious alleles in the gene. DADA2 carriers harbor a single pathogenic variant in and are mostly considered healthy and asymptomatic.

View Article and Find Full Text PDF

The deficiency of adenosine deaminase 2 (DADA2) is an autosomal recessive disorder caused by loss of function mutations in the ADA2 gene (previously the CECR1 gene) on chromosome 22q11. The clinical spectrum of the disease is remarkably broad, and its presentations mimic features of polyarteritis nodosa, such as livedoid rash, hematological abnormalities (e.g.

View Article and Find Full Text PDF

Background/purpose: Our objective was to investigate real-world outcomes and treatment strategies in individuals affected by DADA2 using over 10-year period real-life experience.

Methods: This descriptive analysis encompassed all adult/pediatric patients with DADA2 from our Vasculitis Research Center prospective database. Patients on anti-TNF therapy have been specifically examined, analyzing the treatment's duration, indications, and outcomes.

View Article and Find Full Text PDF
Article Synopsis
  • Adenosine deaminase 2 (DADA2) deficiency is an autoinflammatory disease caused by mutations in the ADA2 gene, leading to various symptoms and potential complications like renal subcapsular hematoma.
  • An 18-year-old female with a history of optic neuritis experienced severe flank pain and inflammatory symptoms, and imaging confirmed bilateral renal subcapsular hematomas, leading to the consideration of DADA2 based on her symptoms and family history.
  • The patient was treated successfully with immunosuppressives, resulting in significant improvement and reduction of the hematomas, highlighting the importance of early diagnosis and treatment in managing DADA2 effectively.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!